

**EPHMRA**  
**ANATOMICAL CLASSIFICATION**  
**GUIDELINES 2020**

**Section B**

**Changed Classes/Guidelines**

**Final Version**

**Date of issue: 19<sup>th</sup> December 2019**

<b>A2B</b>	<b>ANTIULCERANTS</b>  Combinations of specific antiulcerants with other substances, such as anti-infectives against <i>Helicobacter pylori</i> , antispasmodics, gastroprokinetics, that are for ulcers, gastro-oesophageal reflux disease or similar conditions are classified according to the antiulcerant substance. For example, proton pump inhibitors in combination with these anti-infectives are classified in A2B2. Combinations of antiulcerants with non-steroidal anti-inflammatories where the antiulcerant is present for gastric protection are classified in M1A1.	r2020
A2B1	<b>H2 antagonists</b>  Includes, for example, cimetidine, famotidine, nizatidine, ranitidine, roxatidine. Combinations of low dose H2 antagonists with antacids are classified with antacids in A2A6.	R2002
A2B2	<b>Proton pump inhibitors</b>  Includes esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole. Combinations of proton pump inhibitors with gastroprokinetics for ulcers, gastro-oesophageal disease or similar conditions are classified here.	r2020
A2B3	<b>Prostaglandin antiulcerants</b>  Includes misoprostol, enprostil.	
A2B4	<b>Bismuth antiulcerants</b>  Includes combinations with antacids.	
A2B9	<b>All other antiulcerants</b>  Includes all other products containing substances with antiulcerant action where the type of substance is not specified in classes A2B1 to A2B4. Combinations of antiulcerants with antispasmodics are classified in A2B1 to A2B9 according to the type of antiulcerant. Combinations of low dose H2 antagonists with antacids are classified with antacids in A2A6. Included are, eg carbenoxolone, gefarnate, pirenzepine, proglumide, sucralfate and sofalcone. Herbal combinations are classified in A2X.  In Japan, Korea and Taiwan only, sulpiride and other psycholeptics indicated for ulcer use are also included in this group, whilst in all other countries, these compounds are classified in N5A9.  Products containing rebamipide for gastric mucosal protection are classified here. Products containing rebamipide and indicated for dry eye are classified in S1K9.	r2020
<b>A2C</b>	Out of use	D2018
<b>A2X</b>	<b>OTHER STOMACH DISORDER PRODUCTS</b>	I2018

Includes herbal preparations and also plain alginic acid. Combinations of antacids with alginic acid are in A2A1.
---

<b>A3</b>	<b>FUNCTIONAL GASTRO-INTESTINAL DISORDER DRUGS</b>	<b><u>R2003</u></b>
<b>A3A</b>	<b>PLAIN ANTISPASMODICS AND ANTICHOLINERGICS</b>	R1993
	Includes all plain synthetic and natural antispasmodics and anticholinergics.	
<b>A3B</b>	Out of use; can be reused.	
<b>A3C</b>	<b>ANTISPASMODIC/ATARACTIC COMBINATIONS</b>	
	This group includes combinations with tranquillisers, meprobamate and/or barbiturates except when they are indicated for disorders of the autonomic nervous system and neurasthenia, in which case they are classified in N5B4.	
<b>A3D</b>	<b>ANTISPASMODIC/ANALGESIC COMBINATIONS</b>	R1997
	This group includes combinations with analgesics. Products also containing either tranquillisers or barbiturates and analgesics to be also classified in this group. Antispasmodics indicated exclusively for dysmenorrhoea are classified in G2X1.	
<b>A3E</b>	<b>ANTISPASMODICS COMBINED WITH OTHER PRODUCTS</b>	r2020
	Includes all other combinations not specified in A3C, A3D and A3F. Combinations of antispasmodics and antacids are classified in A2A3; combinations of antispasmodics with antiulcerants are classified in A2B1 to A2B9 according to the type of antiulcerant. Combinations of antispasmodics with antiflatulents are classified here.	
<b>A3F</b>	<b>GASTROPROKINETICS</b>	r2020
	This group includes products used for dyspepsia and gastro-oesophageal reflux. Compounds included are: alizapride, bromopride, cisapride, clebopride, cinitapride, domperidone, levosulpiride, metoclopramide, trimebutine. Prucalopride is classified in A6A9.	
	Combinations of gastroprokinetics with other substances are classified here if used for dyspepsia or gastro-oesophageal reflux. Combinations of gastroprokinetics with antiulcerants for ulcers, gastro-oesophageal disease or similar conditions are classified in A2B.	
<b>A3G</b>	<b>GASTRO-INTESTINAL SENSORIMOTOR MODULATORS</b>	r2019
	Products which are specifically developed to modulate the multiple symptoms of irritable bowel syndrome (IBS). Includes alosetron, tegaserod.	
	Linaclotide (290mcg) indicated for IBS-C (irritable bowel syndrome with constipation) is classified here; linaclotide (145mcg) indicated for chronic constipation is classified in A6A9. Products containing linaclotide for both chronic constipation and for IBS-C are classified here when there is no distinction by strength. Lubiprostone (8mcg) indicated for IBS-C is classified here; lubiprostone	

(24mcg) indicated for chronic constipation is classified in A6A9. Products containing plecanatide indicated for chronic constipation and IBS-C are classified here. Other drugs for constipation, including laxatives, are classified in A6A.

<b>A7</b>	<b>INTESTINAL DISORDER PRODUCTS</b>  Products for functional gastro-intestinal disorders are in A3 and products for constipation and bowel cleansing are in A6.	r2019
<b>A7A</b>	<b>INTESTINAL ANTI-INFECTIVES</b>  Includes all products containing one or more intestinal anti-infectives with or without other substances that are used for diarrhoea and/or hepatic encephalopathy. Sulphonamides and special antibacterials such as polymyxin, neomycin, vancomycin or colistin in oral form, when mainly indicated as antidiarrhoeals are included in this group. Combinations with motility inhibitors, intestinal adsorbents and micro-organisms are also included.  Products containing rifaximin for either diarrhoea or hepatic encephalopathy are classified here. Products containing fidaxomicin for <i>Clostridium difficile</i> intestinal infections are classified here.	r2019
<b>A7B</b>	<b>INTESTINAL ADSORBENT ANTIDIARRHOEALS</b>  Includes products such as kaolin and pectin. Combinations with micro-organisms are also included.	r2011
<b>A7C</b>	Out of use; can be reused.	
<b>A7D</b>	Out of use; can be reused.	
<b>A7E</b>	<b>INFLAMMATORY BOWEL DISORDER PRODUCTS</b>  Includes products for inflammatory bowel disorders. Immunosuppressant products used for inflammatory bowel disorders as well as other conditions are classified in L4, for example in L4B (anti-TNF products).	R2017
<b>A7E1</b>	<b>Intestinal aminosalicylate products</b>  Includes products containing balsalazide, mesalazine, olsalazine, sulfasalazine and similar aminosalicylates for inflammatory bowel disorders. Products containing aminosalicylates and indicated for rheumatoid arthritis are classified in M1C.	I2017
<b>A7E2</b>	<b>Intestinal corticosteroid products</b>  Includes products containing corticosteroids for inflammatory bowel disorders.	I2017
<b>A7E9</b>	<b>Inflammatory bowel disorder products, other</b>  Includes other products for inflammatory bowel disorders. Products containing vedolizumab and indicated for inflammatory bowel disease only are classified here.  Products containing disodium cromoglicate and indicated for food allergy are	r2019

	classified here.	
	Darvadstrocel (allogenic stem cells) for perianal fistulae in Crohn's disease are classified here.	
<b>A7F</b>	<b>ANTIDIARRHOEAL MICRO-ORGANISMS</b>	r2020
	Includes micro-organisms such as lactobacillus acidophilus which are indicated for the treatment of diarrhoeal disease. Excluded are combinations with other antidiarrhoeals such as anti-infectives, motility inhibitors, and intestinal adsorbents. Products containing racecadotril are classified in A7X.	
<b>A7G</b>	<b>ORAL ELECTROLYTE REPLACERS</b>	I1993
	Oral electrolyte replacers are included in this group where diarrhoeal disease has been indicated. Intravenous preparations are included in K.	
<b>A7H</b>	<b>MOTILITY INHIBITORS</b>	I1993
	Includes narcotic derivatives such as loperamide, diphenoxylate and paregoric. Combinations with intestinal adsorbents and micro-organisms are also included.	
<b>A7X</b>	<b>INTESTINAL DISORDER PRODUCTS, OTHER</b>	r2020
	Includes other products for intestinal disorders, including antidiarrhoeal products. Products containing racecadotril only, or in combination with micro-organisms, are classified here.	

<b>A10M</b>	<b>GLINIDE ANTIDIABETICS</b>	I2009
A10M1	<b>Glinide antidiabetics, plain</b>  Includes plain products containing repaglinide, nataglinide, mitiglinide, etc.	I2009
A10M3	<b>Glinide and biguanide antidiabetic combinations</b>  Includes combinations of glinide antidiabetics with biguanides.	I2009
A10M9	<b>Glinide antidiabetic combinations, other</b>  Includes combinations of glinide antidiabetics with other antidiabetics where there is no other appropriate class.	I2009
<b>A10N</b>	<b>DPP-IV INHIBITOR ANTIDIABETICS</b>	I2009
A10N1	<b>DPP-IV inhibitor antidiabetics, plain</b>  Includes plain products containing denagliptin, saxagliptin, sitagliptin, vildagliptin, etc.	I2009
A10N3	<b>DPP-IV inhibitor and biguanide antidiabetic combinations</b>  Includes combinations of DPP-IV inhibitors with biguanides.	I2009
A10N9	<b>DPP-IV inhibitor antidiabetic combinations, other</b>  Includes combinations of DPP-IV inhibitors with other antidiabetics where there is no other appropriate class. Combinations of a DPP-IV with a glitazone and a biguanide are classified in A10N9. Combinations of a DPP-IV inhibitor with an SGLT2 inhibitor and a biguanide are classified in A10P9.	r2020
<b>A10P</b>	<b>SGLT2 INHIBITOR ANTIDIABETICS</b>	R2016
A10P1	<b>SGLT2 inhibitor antidiabetics, plain</b>  Includes plain products containing SGLT2 inhibitors, eg canagliflozin, dapagliflozin, empagliflozin, etc.	I2016
A10P3	<b>SGLT2 inhibitor and biguanide antidiabetic combinations</b>  Includes combinations of SGLT2 inhibitors with biguanides.	I2016
A10P5	<b>SGLT2 inhibitor and DPP-IV inhibitor antidiabetic combinations</b>  Includes combinations of SGLT2 inhibitors with DPP-IV inhibitors.	I2017

A10P9	<b>SGLT2 inhibitor antidiabetic combinations, other</b>	r2020
-------	---	-------

<p><b>A10S</b></p>	<p>Includes combinations of SGLT2 inhibitors with other oral antidiabetics where there is no other appropriate class. Combinations of an SGLT2 inhibitor with a DPP-IV inhibitor and a biguanide are classified here.</p> <p><b>GLP-1 AGONIST ANTIDIABETICS</b></p> <p>Includes glucagon-like peptide 1 receptor agonist antidiabetics, eg exenatide, liraglutide, lixisenatide. Combinations of GLP-1 agonist antidiabetics with human insulins or analogues are classified in A10C9.</p> <p>Products containing oral forms of GLP-1 agonists for diabetes are classified here.</p> <p>Products containing liraglutide for weight management only are classified in A8A.</p>	<p>r2020</p>
<p><b>A10X</b></p>	<p><b>OTHER DRUGS USED IN DIABETES</b></p>	<p>R2010</p>
<p>A10X1</p>	<p><b>Antidiabetic multitherapy combination products</b></p> <p>Includes combinations of antidiabetics with cardiovascular drugs where the aim is to treat both the diabetes and the cardiovascular condition. For example, rosiglitazone in combination with simvastatin. Also includes combinations of antidiabetics with anti-obesity drugs where the aim is to treat both the diabetes and the obesity. For example, metformin in combination with sibutramine.</p>	<p>I2010</p>
<p>A10X9</p>	<p><b>Other drugs used in diabetes</b></p> <p>Includes products used for the treatment of diabetes, as well as adjuvant therapy in the treatment and prevention of conditions associated with or developing from diabetes.</p> <p>Includes aldose reductase inhibitors (eg epalrestat, tolrestat), guar gum and glucose products specifically intended for the treatment of hypoglycaemic shock.</p> <p>Teas and other herbal extracts used as adjuvant therapy are classified here.</p>	<p>I2010</p>

<b>A16</b>	<b>OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS</b>	
<b>A16A</b>	<p data-bbox="308 215 1401 259"><b>OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS</b></p> <p data-bbox="308 286 1401 365">Includes all alimentary tract and metabolism products not classified elsewhere. Oral preparations containing procaine are classified in A13A1.</p> <p data-bbox="308 398 1401 510">Products containing one or more oral antidiabetic substances in combination with one or more substances from a cardiovascular class where the aim is to treat both the diabetes and the cardiovascular condition are classified in A10X1.</p> <p data-bbox="308 544 1401 589">Products containing teduglutide for short bowel syndrome are classified here.</p> <p data-bbox="308 622 1401 701">Products containing elapegamase for adenosine deaminase deficiency are classified in L3A9.</p>	r2020

<b>B3</b>	<b>ANTI-ANAEMIC PREPARATIONS</b>	
<b>B3A</b>	<b>HAEMATINICS, IRON AND ALL COMBINATIONS</b>  Any products which contain iron, irrespective of other ingredients (for example, folic acid, vitamin B12, etc.) are classified in B3A.	
<b>B3A1</b>	<b>Plain iron</b>  This class also includes preparations containing ingredients for better absorption and/or reducing agents, such as ascorbic acid, as well as combinations with cobalt.	
<b>B3A2</b>	<b>Iron combination products</b>  Includes all other iron combinations including those containing liver extract and/or folic acid.	R1993
<b>B3B</b>	<b>LIVER EXTRACTS AND COMBINATIONS WITH B12</b>  Includes liver extracts, excluding all preparations not used for anaemia. Oral B12 with intrinsic factor allocated is classified in B3B.	
<b>B3C</b>	<b>ERYTHROPOIETIN PRODUCTS</b>	R1995
<b>B3D</b>	<b>HIF-PH INHIBITORS</b>  Includes products containing HIF-PH (hypoxia-inducible factor prolyl hydroxylase) inhibitors (for example, daprodustat, enarodustat, molidustat, roxadustat, vadadustat, etc) for the treatment of anaemia in chronic kidney disease.	I2020
<b>B3X</b>	<b>OTHER ANTI-ANAEMIC PRODUCTS, INCLUDING FOLIC ACID, FOLINIC ACID</b>  Folinic acid products with more than one indication are classified in V3D.	R2005

<b>B6</b>	<b>ALL OTHER HAEMATOLOGICAL AGENTS</b>	R1996
<b>B6A</b>	Out of use; can be reused from 1999.	D1996
<b>B6B</b>	<b>HYALURONIDASE</b>	
<b>B6C</b>	Out of use	D2020
<b>B6D</b>	<b>HEREDITARY ANGIOEDEMA PRODUCTS</b>  Includes products containing eg C1 inhibitor/conestat alfa, ecallantide, icatibant, etc when indicated for hereditary angioedema.	I2015
<b>B6X</b>	<b>OTHER HAEMATOLOGICAL AGENTS</b>  Includes haemins. Excluded are those preparations used in the treatment of veins and haemorrhoids (C5) and preparations for dermatological use (D3A).	I2020

<b>C</b>	<b>CARDIOVASCULAR SYSTEM</b>	
<b>C1</b>	<b>CARDIAC THERAPY</b>	
<b>C1A</b>	<b>CARDIAC GLYCOSIDES AND COMBINATIONS</b>	
<b>C1A1</b>	<b>Plain cardiac glycosides</b>	r2017
	This group includes all plain cardiac glycosides, either clearly defined chemical entities or standardised plant extracts and combinations of all the aforementioned. Non-standardised plant extracts are classified in C6X.	
<b>C1A2</b>	<b>Cardiac glycoside combinations</b>	r2008
	Excludes combinations with beta-blocking agents (C7B2), calcium antagonists (C8B3), ACE inhibitors (C9B9) and angiotensin-II antagonists (C9D9).	
<b>C1B</b>	<b>ANTI-ARRHYTHMICS</b>	r2020
	This group includes all products which are recommended for use in arrhythmia, disorders of cardiac rhythm and tachycardia, eg ajmaline, quinine, quinidine, procainamide, sparteine, amiodarone or similar, but only when specified as anti-arrhythmics alone. Excludes beta-blocking agents (C7) and calcium antagonists (C8).	
	Products containing mexiletine for cardiac arrhythmias are classified here; products containing mexiletine for non-dystrophic myotonic disorders are classified in M5X.	
<b>C1C</b>	<b>CARDIAC STIMULANTS EXCLUDING CARDIAC GLYCOSIDES</b>	R1994
	This group includes products for the indication hypotension, chiefly sympathomimetic agents eg amezinium methylsulphate used in the treatment of hypotension, but excluding sympathomimetics with predominant bronchodilatory effects used in the treatment of asthma and similar conditions (see R3).	
<b>C1C1</b>	<b>Cardiac stimulants excluding dopaminergic agents</b>	R2003
	Includes plain caffeine. Includes adrenaline/epinephrine products used for anaphylactic shock. Adrenaline combinations with antihistamines are classified here.	
<b>C1C2</b>	<b>Cardiac dopaminergic agents</b>	R1997
	Includes dobutamine, docarpamine, dopamine and ibopamine.	

<b>C1D</b>	<b>CORONARY THERAPY EXCLUDING CALCIUM ANTAGONISTS AND NITRITES</b>  This group includes all other products indicated for coronary insufficiency and angina pectoris. It includes benziodarone, capobenic acid, carbocromen, cinepazet, cinepazic acid, cloridarol, dilazep, dipyridamole, efloxate, etafenone, fenalcomine, flosequinan, hexobendine, imolamine, ivabradine, medibazine, molsidomine, oxyfedrin, trimetazidine, visnadine. Combinations with nitrites are included in C1E and with beta-blockers are included in C7B.	R2007
<b>C1E</b>	<b>NITRITES AND NITRATES</b>  This group includes all nitrites and analogous products and combinations if they are indicated for angina pectoris. Combinations of nitrites with cardiac glycosides are classified in C1A2 and combinations with beta-blockers in C7B.	
<b>C1F</b>	<b>POSITIVE INOTROPIC AGENTS</b>  This group includes substances such as amrinone, milrinone, fenoximone, piroximone, xamoterol.	R1994
<b>C1X</b>	<b>ALL OTHER CARDIAC PREPARATIONS</b>  This group includes substances such as alprostadiol, crateagus glycosides, creatinolphosphate, phosphocreatinine, levocarnitine and ubidecarenone. Combination products are only classified in this group if they contain a substance which is not in the C group.  Products containing tafamidis for transthyretin amyloid polyneuropathy(TAP) only are classified in N7X. Products containing tafamidis for transthyretin amyloid cardiomyopathy (TAC) only are classified here. Products containing tafamidis for both TAP and TAC are classified in N7X.	r2020

<b>C4</b>	<b>CEREBRAL AND PERIPHERAL VASOTHERAPEUTICS</b>	
<b>C4A</b>	<b>CEREBRAL AND PERIPHERAL VASOTHERAPEUTICS</b>  This group includes all products (including citicoline) which are mainly recommended for cerebral vascular diseases or peripheral circulatory disorders excluding venous diseases. Combination products are only classified in this group if they do not belong to group C1-C3, C7-C11.	R2005
C4A1	<b>Cerebral and peripheral vasotherapeutics excluding calcium antagonists with cerebral activity</b>  Products containing phenoxybenzamine alone, and indicated either for hypertension or BPH are classified here. Products containing cinepazide alone and for vasodilation are classified here. Products containing beperminogene perplasmid for improvement of limb ischaemia are classified here.	r2020
C4A2	<b>Calcium antagonists with cerebral activity</b>  Includes, bencyclane, cinnarizine, cyclandelate, flunarizine and nimodipine.	R1993

<b>C10</b>	<b>LIPID-REGULATING/ANTI-ATHEROMA PREPARATIONS</b>  Excludes products intended for weight reduction.	R2005
<b>C10A</b>	<b>CHOLESTEROL AND TRIGLYCERIDE REGULATING PREPARATIONS</b>  Includes all products regulating cholesterol and triglycerides only. Combinations with products of group C4 should be classified here. Combinations with oral antidiabetic substances are classified in A10X1.	r2010
C10A1	<b>Statins (HMG-CoA reductase inhibitors)</b>  Includes atorvastatin, cerivastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin simvastatin.  Combinations of statins with ezetimibe are classified in C10C.	R2006
C10A2	<b>Fibrates</b>  Includes beclobrate, bezafibrate, ciprofibrate, clofibrate, clofibrade, etofibrate, fenofibrate, gemfibrozil, simfibrate.	I1997
C10A3	<b>Ion-exchange resins</b>  Includes cholestyramine, colestipol, polidexide.	I1997
C10A4	<b>PCSK9 inhibitors</b>  Includes proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, eg alirocumab, evolocumab.	I2016
C10A9	<b>All other cholesterol/triglyceride regulators</b>  Includes ezetimibe, probucol, tiadenol, pyridinolcarbamate and all other products excluding those in C10B.  Combinations of ezetimibe with statins are classified in C10C.  Nicotinic acid derivatives if indicated in this area are classified here, eg acipimox.  Products containing volanesorsen for familial chylomicronaemia syndrome (FCS) are classified here.	r2020
<b>C10B</b>	<b>ANTI-ATHEROMA PREPARATIONS OF NATURAL ORIGIN</b>  This class includes products of natural origin used for the prevention and treatment of arteriosclerosis, eg omega fatty acids, garlic preparations, lecithin.	I1997

<b>D5</b>	<p><b>NONSTEROIDAL PRODUCTS FOR INFLAMMATORY SKIN DISORDERS</b></p> <p>Includes products for psoriasis, hyperkeratosis, ichthyosis, eczema, dermatitis, seborrhoea. Psoralens are classified here when used for inflammatory conditions. Excluded from this class are combinations with antibacterials (D6A), antifungals (D1A) and products specifically indicated in acne (D10A). Sulphur baths which contain other substances besides sulphur and are not used for dermatological purposes, are classified in M2A.</p>	<b>r2019</b>
<b>D5A</b>	<p><b>TOPICAL ANTIPSORIASIS PRODUCTS</b></p> <p>Includes products containing substances such as tar, coal tar, ichthammol, dithranol, psoralens, salicylic acid for the treatment of psoriasis. These products may also be for other inflammatory skin conditions. Products containing corticosteroids in combination with coal tar or salicylic acid for psoriasis are classified here. These products may also be for other inflammatory skin conditions.</p> <p>Includes products consisting of coal tar or calcipotriol, alone or in combination, when indicated for psoriasis.</p>	<b>r2019</b>
<b>D5B</b>	<p><b>SYSTEMIC ANTIPSORIASIS PRODUCTS</b></p> <p>Includes products for the treatment of psoriasis. These products may also be for other inflammatory skin conditions. Products containing ixekizumab, secukinumab or ustekinumab and indicated for psoriasis and also other non-skin conditions, eg arthritis, are classified in L4C. Psoriatic arthritis is defined as a skin condition.</p> <p>Apremilast is classified here if only for psoriatic skin conditions. Products containing apremilast for multiple conditions are classified in L4X.</p>	<b>r2020</b>
<b>D5X</b>	<p><b>OTHER NONSTEROIDAL PRODUCTS FOR INFLAMMATORY SKIN DISORDERS</b></p> <p>Includes nonsteroidal products for inflammatory skin disorders which are not indicated for psoriasis. Specific topical immunomodulators for dermatitis are classified here.</p> <p>Products containing ingenol mebutate or diclofenac gel that are indicated for actinic keratosis are classified here. Products containing aminolaevulinic acid for actinic keratosis, basal cell carcinoma or Bowen syndrome are classified in L1X8. Products containing topical fluorouracil for actinic keratosis are classified in L1B.</p> <p>Products containing dupilumab for atopic dermatitis only are classified here. Products containing dupilumab for both atopic dermatitis and asthma are classified in L4C.</p>	<b>r2019</b>

<b>G</b>	<b>GENITO-URINARY SYSTEM AND SEX HORMONES</b>	
<b>G1</b>	<b>GYNAECOLOGICAL ANTI-INFECTIVES</b>  The need for a systematic approach to classifying combination products (ie those containing two or more different gynaecological anti-infectives) has led to the adoption of a hierarchical system with a G1A (trichomonacide) ingredient taking precedence over a G1B (antifungal), G1B over G1C, etc.	
<b>G1A</b>	<b>TRICHOMONACIDES</b>  Includes metronidazole, nifuratel, nimorazole, ornidazole, secnidazole, tinidazole. Products for both trichomoniasis and amoebiasis are classified here.	r2020
<b>G1A1</b>	<b>Systemic trichomonacides</b>  Includes all oral solid, suspension and oral liquid forms of metronidazole and other trichomonacides.	R2004
<b>G1A2</b>	<b>Topical trichomonacides</b>  Includes vaginal tablets and vaginal suppositories of metronidazole and other trichomonacides. Rectal suppositories to be classified in J8.	
<b>G1A3</b>	<b>Combined forms of trichomonacides</b>  Includes those packs of metronidazole and other trichomonacides which contain both systemic and topical forms for the treatment of gynaecological conditions eg Flagyl Compak.	
<b>G1B</b>	<b>GYNAECOLOGICAL ANTIFUNGALS</b>  Includes antifungal products indicated only for gynaecological conditions. These can be specific gynaecological forms, eg ovules, or systemic forms. Excluded are antifungals for dermatological use which are classified in D1A or J2A and antifungals for systemic infections which are classified in J2A. If a product is indicated for both systemic and gynaecological infections, then it is classified in J2A.	R1999
<b>G1C</b>	<b>GYNAECOLOGICAL ANTIBACTERIALS</b>  Includes those products indicated for gynaecological conditions. Excluded are antibacterials for dermatological use which are classified in D6A, and general systemic antibacterials which are classified in J1 and J3.	r2009

<b>G2</b>	<b>OTHER GYNAECOLOGICALS</b>	
<b>G2A</b>	<b>UTEROTONIC PRODUCTS</b>	r2019
	Includes products used to induce labour (including delivery of placenta) and/or to reduce postpartum haemorrhage. Includes oxytocics and prostaglandins E1 and E2, and products used for cervical dilatation.	
<b>G2B</b>	<b>TOPICAL CONTRACEPTIVES</b>	
<b>G2C</b>	Out of use; can be reused from 2000.	D1997
<b>G2D</b>	<b>PROLACTIN INHIBITORS</b>	R1999
	This group includes products used as prolactin inhibitors and containing bromocriptine, cabergoline, pergolide, quinagolide, terguride etc. Bromocriptine in lower doses (1 mg, 2.5 mg) for sexual disorders is classified here; higher doses for parkinsonism are in N4A. In Japan, bromocriptine is classified in N4A.	
<b>G2E</b>	<b>LABOUR INHIBITORS</b>	I1997
	This group includes products acting as labour inhibitors eg ritodrine.	
<b>G2F</b>	<b>TOPICAL SEX HORMONES</b>	r2019
	This group includes all topical hormones and/or steroids indicated for gynaecological conditions. Transdermal patches and vaginal formulations containing oestrogens and intended for a systemic effect are classified in G3C.	
<b>G2X</b>	<b>OTHER GYNAECOLOGICAL PRODUCTS</b>	I1997
<b>G2X1</b>	<b>Gynaecological antispasmodics</b>	I1997
	This group includes oral analgesics and antispasmodics indicated exclusively for dysmenorrhoea.	
<b>G2X9</b>	<b>Other gynaecologicals</b>	r2020
	Specific products included in this class are non-hormonal anti-inflammatories (eg benzydamine) which are indicated specifically to treat gynaecological conditions. Includes lubricants for intimate vaginal use only. Includes products (lactogogues) for the promotion of milk production.	
	Products containing paroxetine (7.5mg daily) and indicated for menopausal vasomotor symptoms are classified here.	
	Products containing bremelanotide or flibanserin and indicated for hypoactive sexual desire disorder (HSDD) in women are classified here.	

<b>G4</b>	<b>UROLOGICALS</b>	
<b>G4A</b>	<b>URINARY ANTI-INFECTIVES AND ANTISEPTICS</b>	
G4A1	<b>Urinary antibacterials</b>  This group includes those products containing an antibacterial where the only indication is for urinary tract infections. Sulphonamides are generally classified in J3 and other antibacterials in J1. All trimethoprim formulations are classified in J1E. Combinations with halogenated or non-halogenated quinolones are classified in G4A2.	r2009
G4A2	<b>Urinary non-halogenated quinolones</b>  Includes products containing non-halogenated quinolones which are only indicated for urinary tract infections. Systemic products containing halogenated quinolones (plain) are classified in J1G. Combinations of halogenated or non-halogenated quinolones with other substances (including antibacterials) and indicated for urinary tract infections are classified in G4A2.	R2009
G4A3	Out of use; can be reused from 2010.	D2007
G4A9	<b>Other urinary antiseptics</b>  Includes such products as nitrofurantoin and methenamine. Irrigating solutions are classified in Group K.	I2007
<b>G4B</b>	Out of use; can be reused from 2010.	D2007
<b>G4C</b>	<b>BPH (BENIGN PROSTATIC HYPERTROPHY) PRODUCTS</b>	R2007
G4C1	Out of use	D2012
G4C2	<b>BPH alpha-adrenergic antagonists, plain</b>  Includes products containing alpha-adrenergic antagonists, such as alfuzosin, tamsulosin. Products containing terazosin, for BPH or hypertension, are classified here. Products containing doxazosin are classified in C2A2. Products containing indoramin, for BPH or hypertension, are classified in C2A2, or in N2C9 if indicated for migraine.	r2015
G4C3	<b>BPH 5-alpha testosterone reductase inhibitors (5-ARI), plain</b>  Includes products containing 5-alpha testosterone reductase inhibitors (5-ARI), such as dutasteride and finasteride.  Products containing finasteride 5mg and for BPH are classified here. Products containing finasteride 1mg and for alopecia are classified in D11A.	r2018

G4C4	<b>BPH alpha-antagonists and 5-ARIs, combinations</b>	I2012
------	---	-------

	Includes products containing an alpha-adrenergic antagonist and a 5-alpha testosterone reductase inhibitor. If one or more additional substances are included, then the product is classified in G4C7.	
G4C7	<b>BPH 5-ARIs and/or alpha-antagonists in combination with other substances</b>	r2020
	Includes products containing eg tamsulosin with tolterodine, tamsulosin with a substance of natural origin, or tamsulosin with corticosteroids.	
G4C8	Out of use	D2012
G4C9	<b>BPH products, other</b>	I2012
	Includes products of herbal or animal origin, as well as homeopathic products, for BPH. Products containing mepartricine, <i>Serenoa repens</i> , or <i>Pygeum africanum</i> are classified in G4C9 if indicated for BPH. This class also includes herbal products for improving prostatic health.	
<b>G4D</b>	<b>URINARY INCONTINENCE PRODUCTS</b>	I2007
G4D4	<b>Urinary incontinence products</b>	I2007
	This group includes preparations for urinary incontinence eg those containing duloxetine, flavoxate, oxybutynin, tolterodine. Products of natural origin and homeopathic products are classified in G4D8.	
G4D8	<b>Urinary incontinence products of natural origin</b>	I2007
	Includes products of herbal or animal origin, as well as homeopathic products, for urinary incontinence. Also includes collagen injections for incontinence.	

<b>H</b>	<b>SYSTEMIC HORMONAL PREPARATIONS (EXCLUDING SEX HORMONES)</b>	
<b>H1</b>	<b>PITUITARY AND HYPOTHALAMIC HORMONES</b>	R1995
<b>H1A</b>	<b>ACTH</b>  ACTH and synthetic analogues.	
<b>H1B</b>	Out of use; can be reused.	
<b>H1C</b>	<b>HYPOTHALAMIC HORMONES</b>	R2003
H1C1	<b>Gonadotrophin-releasing hormones</b>  Includes eg buserelin, deslorelin, gonadorelin, goserelin, nafarelin, leuprorelin, triptorelin, when not used as cytostatics. When these substances are used as cytostatics, they are classified in L2A3. Products containing gonadotrophin-releasing hormone analogues for cancer and also for other conditions, are classified in L2A3.	r2020
H1C2	<b>Antigrowth hormones</b>  Products for acromegaly are classified here. Lanreotide, octreotide and somatostatin are classified here. Somatostatin, when used as a haemostyptic, is classified in B2G. Growth hormone antagonists, such as pegvisomant, are classified here.	r2020
H1C3	<b>Antigonadotrophin-releasing hormones</b>  Cetrorelix and ganirelix are classified here.	I2003

<b>H2</b>	<b>SYSTEMIC CORTICOSTEROIDS</b>	
<b>H2A</b>	<b>SYSTEMIC CORTICOSTEROIDS, PLAIN</b>	
	Includes all systemic products containing one or more corticosteroid(s) and no other active ingredient, with or without lignocaine.	
H2A1	<b>Injectable corticosteroids, plain</b>	R1993
H2A2	<b>Oral corticosteroids, plain</b>	R1993
H2A3	<b>Other systemic corticosteroids, plain</b>	r2017
	Includes suppositories. Corticosteroids to treat inflammatory intestinal disorders are classified in A7E2.	
<b>H2B</b>	<b>SYSTEMIC CORTICOSTEROID COMBINATIONS</b>	r2020
	Systemic products containing one or more corticosteroid(s) and one or more other active ingredient(s) (eg antihistamine). Also includes extracts containing natural corticosteroids, but excluding products classified in the following groups:	
	A7E2 – Intestinal anti-inflammatory agents	
	H4X – Liver extracts with small doses of corticosteroids (mainly in Italy).	
	G3X - Gland extracts (mammary, placenta, etc) and corticoid extracts mainly indicated for sexual disorders.	
	G4C7 – Corticosteroids with alpha-adrenergic antagonists.	
	M1B - Corticosteroids with anti-inflammatory agents, analgesics, muscle relaxants, etc.	
	R1B – Systemic nasal preparations	
	R3D, R3F, R3L3 - Anti-asthmatic inhalants acting topically on the bronchioles.	

J1P3	<b>Carbacephems</b>  Includes loracarbef.	I1997
J1P9	<b>All other beta-lactam antibacterials</b>	I1997
<b>J1X</b>	<b>OTHER ANTIBACTERIALS</b>  Includes all other systemic antibacterials which do not fit into J1A-J1P or J3A. Combinations with products in J1K, J1L, J1M, J1P, and J3A are classified in these groups respectively.	R2006
J1X1	<b>Glycopeptide antibacterials</b>  Includes teicoplanin, vancomycin. Products containing vancomycin (oral forms) for intestinal infections are classified in A7A.	r2017
J1X2	<b>Polymyxins</b>  Includes colistin, polymyxin. These substances, if mainly indicated as antidiarrhoeals, are classified in A7A.	I1994
J1X9	<b>All other antibacterials</b>  Includes all systemic antibacterials which do not fit into J1A-J1X2, eg daptomycin, fosfomicin, fusidic acid, linezolid, novobiocin, plain sulbactam, pristinamycin, spectinomycin, and tigecycline. Formulations of fosfomicin with broad spectrum penicillins are in J1C and formulations with cephalosporins are in J1D.	r2020

<b>J7</b>	<b>VACCINES</b>	
<b>J7A</b>	Out of use	D2014
<b>J7B</b>	<b>COMBINATIONS OF VACCINES</b>	r2018
	Included are combinations of vaccines for protection against more than one virus and/or bacteria and/or protozoa.	
J7B1	<b>Combinations with a tetanus component</b>	
J7B2	<b>Combinations with measles and/or mumps</b>	R2007
	MMR vaccine is classified here.	
J7B3	<b>All other combinations</b>	
<b>J7C</b>	Out of use	D2014
<b>J7D</b>	<b>BACTERIAL VACCINES</b>	r2018
	Includes separate classes for vaccines against only one bacterial group. For vaccines against a combination of bacteria or viruses, see J7B.	
J7D1	<b>Pneumococcal vaccines</b>	I2014
J7D2	<b>Meningococcal vaccines</b>	I2014
J7D3	<b>Haemophilus B vaccines</b>	I2014
J7D4	<b>Typhoid vaccines</b>	I2014
	Includes vaccines against typhoid and paratyphoid. Vaccines against typhus are classified in J7D9.	
J7D5	<b>Tetanus vaccines</b>	I2014
J7D6	<b>Tuberculosis vaccines</b>	r2020
	Products containing BCG vaccine for cancer are classified in L1X9; those for general immunostimulation are classified in L3A9.	
J7D7	<b>Cholera vaccines</b>	I2014
J7D9	<b>All other bacterial vaccines</b>	I2014
	Includes all other vaccines against one bacterial group, eg diphtheria, pertussis, typhus.	
L1H5	<b>Protein kinase inhibitor antineoplastics, CDK 4/6</b>	I2019

	Includes products containing abemaciclib, palbociclib, ribociclib, etc. Products containing both ribociclib and letrozole are classified here.	
L1H9	<b>Protein kinase inhibitor antineoplastics, other</b>  Includes all other protein kinase inhibitor antineoplastics, for example those inhibiting HER-2, JAK 1-2, BTK, Pi3K, etc.  Includes acalabrutinib, apatinib, axitinib, cabozantinib, erdafitinib, everolimus, ibrutinib, idelalisib, lapatinib, lenvatinib, midostaurin, neratinib, nintedanib, pazopanib, regorafenib, ruxolitinib, sorafenib, sunitinib, temsirolimus, tivozanib, vandetanib, etc.	r2020
L1J	<b>PROTEASOME INHIBITOR ANTINEOPLASTICS</b>  Includes products containing proteasome inhibitors for neoplasms, eg bortezomib, carfilzomib, ixazomib, etc.	I2018
L1X	<b>ALL OTHER ANTINEOPLASTICS</b>	R2018
L1X1	<b>Alternative preparations for cancer therapy</b>  Includes products derived from Viscum (mistletoe).	r2018
L1X2	<b>Lidomide antineoplastics</b>  Includes products containing lenalidomide, pomalidomide or thalidomide for multiple myeloma and other cancers.  Products containing thalidomide for both cancer and erythema nodosum leprosum (ENL) are classified here. Products containing thalidomide for ENL only are classified in L4X.	I2019
L1X3	<b>HDAC inhibitor antineoplastics</b>  Includes products containing HDAC inhibitors for neoplasms, eg belinostat, entinostat, panobinostat, romidepsin, tucidinostat, vorinostat, etc.	I2018
L1X4	<b>PARP inhibitor antineoplastics</b>  Includes products containing niraparib, olaparib, rucaparib, talazoparib, veliparib, etc.	I2019

L1X5	<p><b>CAR T-cell therapy antineoplastics</b></p> <p>Includes products containing axicabtagene ciloleucel, tisagenlecleucel, etc.</p>	I2019
L1X8	<p><b>Photosensitisers for cancer therapy</b></p> <p>Includes products containing photosensitisers for use in cancer therapy, eg aminolaevulinic acid, methyl aminolaevulinate, methoxsalen, porfimer, talaporfin, temoporfin, etc.</p> <p>Products containing aminolaevulinic acid for actinic keratosis, basal cell carcinoma or Bowen syndrome are classified here. Products containing aminolaevulinic acid for use in diagnostic procedures are classified in T1X.</p> <p>Products containing methoxsalen for other skin conditions such as psoriasis or vitiligo are classified in the appropriate D classes.</p> <p>Products containing vertoporphin for macular degeneration are classified in S1P.</p>	r2019
L1X9	<p><b>All other antineoplastics</b></p> <p>Includes amsacrine, enzymes, estramustine, gallium nitrate, methylhydralazine, mitotane, procarbazine, substituted urea, tasonermin, vosaroxin. Also includes celecoxib for familial adenomatous polyposis (FAP).</p> <p>Products containing aflibercept for cancer are classified here. Products containing aflibercept for macular degeneration are classified in S1P.</p> <p>Includes products containing hedgehog pathway inhibitors, eg glasdegib, sonidegib, vismodegib, etc.</p> <p>Products containing BCG vaccine for cancer are classified here; those for general immunostimulation are classified in L3A9. Products containing BCG vaccine for active immunisation against tuberculosis are classified in J7D6.</p>	r2020

<b>L2</b>	<b>CYTOSTATIC HORMONE THERAPY</b>	I1994
	Includes all types of hormones used primarily in the treatment of cancers, eg adrenocorticoids, progestogens, oestrogens, anti-oestrogens and androgens.	
<b>L2A</b>	<b>CYTOSTATIC HORMONES</b>	I1994
L2A1	<b>Cytostatic oestrogens</b>	I1994
L2A2	<b>Cytostatic progestogens</b>	I1994
L2A3	<b>Cytostatic gonadotrophin-releasing hormone analogues</b>	r2020
	Buserelin, deslorelin, goserelin, nafarelin, leuprorelin and triptorelin are classified here. When these substances are not used as cytostatics they are classified in H1C. Products containing gonadotrophin-releasing hormone analogues for cancer and also for other conditions are classified here.	
L2A9	<b>Other cytostatic hormones</b>	I1994
	Includes substances such as drostanolone, testolactone.	
<b>L2B</b>	<b>CYTOSTATIC HORMONE ANTAGONISTS</b>	I1994
L2B1	<b>Cytostatic anti-oestrogens</b>	R1997
	Includes substances such as tamoxifen, mepitiostane, epitiostanol, toremifene.	
L2B2	<b>Cytostatic anti-androgens</b>	I1994
	Includes substances such as flutamide, nilutamide. Cyproterone acetate (50 mg; injectable forms) is classified here.	
L2B3	<b>Cytostatic aromatase inhibitors</b>	r2019
	Includes aminoglutethamide, anastrozole, exemestane, formestane, letrozole.	
	Products containing both ribociclib and letrozole are classified in L1H5.	
L2B9	<b>Other cytostatic hormone antagonists</b>	R2003
	Includes fulvestrant.	

<b>L3</b>	<b>IMMUNOSTIMULATING AGENTS</b>	I1994
<b>L3A</b>	<b>IMMUNOSTIMULATING AGENTS EXCLUDING INTERFERONS</b>	R2004
L3A1	<b>Colony-stimulating factors</b>  Includes aneastim, empegfilgrastim, filgrastim, lenograstim, molgramostim, pegfilgrastim, sargramostim.	r2018
L3A9	<b>All other immunostimulating agents excluding interferons</b>  Includes cridanimod, glatiramer acetate, interleukin-2, picibanil.  <i>Corynebacterium parvum</i> and levamisole are classified here when used as immunostimulants.  Products containing BCG vaccine for cancer are classified in L1X9; those for general immunostimulation are classified here. Products containing BCG vaccine for active immunisation against tuberculosis are classified in J7D6.  Products containing elapegademase for adenosine deaminase deficiency are classified here.	r2020
<b>L3B</b>	<b>INTERFERONS</b>  Products containing interferons (with or without ribavirin) for multiple indications are classified in L3B. Products containing interferons (with or without ribavirin) for hepatitis only are classified in J5D1.	r2018
L3B1	<b>Interferons, alpha</b>	I1994
L3B2	<b>Interferons, beta</b>  Products containing beta interferons and indicated for multiple sclerosis only are classified in N7A. Products containing beta interferons and indicated for both multiple sclerosis and other conditions are classified here.	R2017
L3B3	<b>Interferons, gamma</b>	I1994
L3B9	<b>Interferons, non-specified</b>	I1994

<b>L4</b>	<b>IMMUNOSUPPRESSANTS</b>	R2010
<b>L4A</b>	Out of use; can be reused from 2013.	D2010
<b>L4B</b>	<b>ANTI-TNF PRODUCTS</b>  Products containing anti-TNF substances are classified here, eg adalimumab, afelimomab, certolizumab pegol, etanercept, golimumab, infliximab. These products can be indicated for multiple conditions, eg rheumatoid arthritis, Crohn's disease, psoriasis.  Products containing apremilast for psoriatic conditions only are classified in D5B. Products containing apremilast for multiple conditions are classified in L4X.	r2020
<b>L4C</b>	<b>INTERLEUKIN INHIBITORS</b>  Includes products containing interleukin inhibitors, eg basiliximab, canakinumab, daclizumab, rilonacept.  Includes interleukin inhibitors indicated for the treatment of rejection in organ transplants and for auto-inflammatory diseases such as CAPS (cryopyrin-associated periodic syndromes).  Products containing tocilizumab or anakinra and indicated for arthritic conditions are classified in M1C. Products containing tocilizumab and indicated for both arthritic conditions and also giant cell arteritis are classified in M1C. Products containing ixekizumab, secukinumab or ustekinumab and indicated for skin conditions such as psoriasis and also other non-skin conditions, eg rheumatoid arthritis, are classified here. Psoriatic arthritis is defined as a skin condition.  Products containing daclizumab and indicated for use in kidney transplantation are classified here. Products containing daclizumab and indicated for multiple sclerosis and other conditions are classified in N7A.  Products containing mepolizumab for asthma only or for asthma and EGPA (eosinophilic granulomatosis with polyangiitis) are classified in R3M.  Products containing dupilumab for atopic dermatitis are classified in D5X. Products containing dupilumab for both atopic dermatitis and asthma are classified here.	r2020

<b>L4X</b>	<p data-bbox="316 127 833 161"><b>OTHER IMMUNOSUPPRESSANTS</b></p> <p data-bbox="316 208 1393 277">Immunosuppressants used in the treatment of rejection in organ transplants are classified here, or in L4C if they contain interleukin inhibitors.</p> <p data-bbox="316 322 1393 501">Includes eg antilymphocyte and antithymocyte immunoglobulins, azathioprine, cyclosporin, muromonab-cd3, mycophenolate mofetil, tacrolimus – unless classified elsewhere because of a specific indication or formulation. For example, ophthalmic cyclosporin for dry eye is classified in S1K9 and dermatological tacrolimus is classified in D5X.</p> <p data-bbox="316 546 1393 651">Products for multiple sclerosis are classified in N7A. Products containing natalizumab and indicated for multiple sclerosis and other conditions are classified in N7A.</p> <p data-bbox="316 696 1393 801">Products containing apremilast for psoriatic skin conditions only, are classified in D5B. Psoriatic arthritis is defined as a skin condition. Products containing apremilast for multiple conditions are classified here.</p> <p data-bbox="316 846 1393 1025">Products containing lenalidomide, pomalidomide or thalidomide for multiple myeloma and other cancers are classified in L1X2. Products containing thalidomide for both cancer and erythema nodosum leprosum (ENL) are classified in L1X2. Products containing thalidomide for erythema nodosum leprosum only are classified here.</p> <p data-bbox="316 1070 1393 1140">Products containing tofacitinib for multiple conditions are classified here. Products containing tofacitinib for rheumatoid arthritis only are classified in M1C.</p> <p data-bbox="316 1184 1393 1290">Products containing leflunomide for multiple conditions are classified here. Products containing leflunomide for rheumatoid arthritis only are classified in M1C.</p> <p data-bbox="316 1335 810 1368">Corticosteroids are not classified here.</p>	r2020
------------	---	-------

<b>M</b>	<b>MUSCULO-SKELETAL SYSTEM</b>	
<b>M1</b>	<b>ANTI-INFLAMMATORY AND ANTI-RHEUMATIC PRODUCTS</b>	
<b>M1A</b>	<b>ANTI-RHEUMATICS, NON-STEROIDAL</b>	r2009
	Includes all non-hormonal anti-inflammatory products for systemic treatment of musculoskeletal inflammation. Products for analgesia only are classified in N2B.	
<b>M1A1</b>	<b>Anti-rheumatics, non-steroidal plain</b>	r2020
	Includes products containing an additional non-therapeutic ingredient or an ingredient to minimise the side-effects of the main active substance. Examples include alkalinizing agents, local anaesthetics or cytoprotectants. For example, combinations of non-steroidals with antiulcerants, where the antiulcerant is for gastric protection, are classified here.	
<b>M1A2</b>	<b>Anti-rheumatics, non-steroidal combination</b>	R2007
	Combination products containing colchicine, or minerals, vitamins, rutin should be classified here. Combinations of anti-inflammatory substances with analgesics for musculoskeletal conditions are classified here. Includes coxib combinations.	
<b>M1A3</b>	<b>Coxibs, plain</b>	R2007
	Includes products that are highly specific to the COX-2 enzyme. At therapeutic doses, they specifically inhibit cyclo-oxygenase-2 (COX-2) but do not inhibit the cyclo-oxygenase-1 (COX-1) isoenzyme. Products in this class include celecoxib, etoricoxib, parecoxib, rofecoxib and valdecoxib.	
<b>M1B</b>	<b>ANTI-RHEUMATIC CORTICOSTEROID COMBINATIONS</b>	
	Includes all systemic steroid combinations specifically or primarily indicated in rheumatic disorders. Examples include corticosteroids with one or more of the following ingredients:  non-hormonal anti-inflammatory agents Analgesics Vitamins muscle relaxants.	

<b>M1C</b>	<p><b>SPECIFIC ANTI-RHEUMATIC AGENTS</b></p> <p>This class includes abatacept, anakinra, tocilizumab, gold preparations, bucillamine, penicillamine and quinolines (eg oxycinchophen). Includes products containing mesalazine, olsalazine, and sulphasalazine if specifically indicated for rheumatic conditions. Products containing aminosalicylates and used for intestinal inflammatory conditions, are classified in A7E1.</p> <p>Azathioprine is in L4X. Products containing methotrexate for rheumatic conditions are classified here; otherwise methotrexate is classified in LIB or in D.</p> <p>Products containing anti-TNF substances are classified in L4B.</p> <p>Products containing tofacitinib, and indicated for rheumatoid arthritis only, are classified here. Products containing tofacitinib for multiple conditions are classified in L4X.</p> <p>Products containing leflunomide, and indicated for rheumatoid arthritis only, are classified here. Products containing leflunomide for multiple conditions are classified in L4X.</p> <p>Products containing interleukin inhibitors and only indicated for arthritic conditions are classified here, eg anakinra. Products containing tocilizumab and indicated for both arthritis and giant cell arteritis are classified here. Other interleukin inhibitors indicated for multiple conditions including arthritis are classified in L4C.</p> <p>Psoriatic arthritis is defined as a skin condition.</p>	r2020
------------	---	-------

<b>M5</b>	<b>OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM</b>	
<b>M5A</b>	Out of use; can be reused from 1996.	D1993
<b>M5B</b>	<b>BONE CALCIUM REGULATORS</b>	R2002
	Calcitonin products are classified in H4A. Products containing calcium only are classified in A12A and fluoride products are classified in A12C2.	
<b>M5B1</b>	Out of use; can be reused from 2010.	D2007
<b>M5B2</b>	Out of use; can be reused from 2010.	D2007
<b>M5B3</b>	<b>Bisphosphonates for osteoporosis and related disorders</b>	I2007
	Includes products indicated and used mainly for osteoporosis and Paget's disease, eg those containing alendronic acid, etidronic acid, ibandronic acid, risedronic acid, zoledronic acid, when indicated for these conditions. Combinations of bisphosphonates with calcium, calcitriol or colecalciferol are also classified here.	
<b>M5B4</b>	<b>Bisphosphonates for tumour-related calcium disorders</b>	I2007
	Includes products indicated and used mainly for tumour-related calcium disorders (eg hypercalcaemia of malignancy) eg those containing clodronic acid, etidronic acid, ibandronic acid, pamidronic acid, zoledronic acid when indicated for these conditions.	
<b>M5B9</b>	<b>Other bone calcium regulators</b>	I2002
	Includes other specific products which are used for osteoporosis (eg ipriflavone).	
<b>M5X</b>	<b>ALL OTHER MUSCULOSKELETAL PRODUCTS</b>	r2020
	Includes all other products for disorders of the musculoskeletal system not classified elsewhere. Includes musculoskeletal products containing substances such as cartilage extract, chondroitin, etc. Products containing chondroitin and glucosamine alone or in combination with other substances are classified here. Combinations of glucosamine with nonsteroidal anti-inflammatories are classified in M1A2. Topical glucosamine and chondroitin products are classified in M2A.	
	Includes hydroquinine indicated for restless leg syndrome.	
	Includes herbal products used for musculoskeletal pain.	
	Products containing burosumab for X-linked hypophosphataemia are classified here.	
	Products containing mexiletine for non-dystrophic myotonic disorders are classified here; products containing mexiletine for cardiac arrhythmias are	

	classified in C1B .	
--	---------------------	--

<b>N</b>	<b>NERVOUS SYSTEM</b>	R2007
<b>N1</b>	<b>ANAESTHETICS</b>	
<b>N1A</b>	<b>ANAESTHETICS, GENERAL</b>	
<b>N1A1</b>	<b>Inhalation general anaesthetics</b>  Gas cylinders for hospital use are classified here.	r2010
<b>N1A2</b>	<b>Injectable general anaesthetics</b>  Also includes injectable sedatives, eg midazolam, given for the induction and maintenance of anaesthesia, for the sedation of ventilator - dependent patients (intubation) and as sedative/premedication for surgical procedures.  Products containing esketamine for general anaesthesia are classified here; products containing esketamine for depression are classified in N6A9.	r2020
<b>N1B</b>	<b>ANAESTHETICS, LOCAL</b>  Includes local injectable and topical anaesthetics intended for surgery, surgical and medical procedures, and associated pain relief. Included are eg articaine, bupivacaine, chloroprocaine, dibucaine, etidocaine, lidocaine, mepivacaine, mesocaine, prilocaine, procaine, ropivacaine, tetracaine.  Only single active ingredient products or combinations of different local anaesthetics are classified under N1B. Specific single-ingredient ophthalmological local anaesthetics are classified in S1H. Combinations of local anaesthetics with vasoconstrictors eg adrenaline, are classified here. Products containing either local anaesthetics only or other substances in combination with local anaesthetics and intended for indications other than surgery or associated pain relief are classified under eg A1A, D4A, R2A or S1H according to the indication. Products containing local anaesthetics used specifically for premature ejaculation are classified in G4X.	R2007
<b>N1B1</b>	<b>Anaesthetics local, medical injectables</b>  Injectable local anaesthetic products intended for local, regional or central nerve block except for products intended for nerve block in dental practice which should be classified in N1B2.	I1998
<b>N1B2</b>	<b>Anaesthetics local, dental injectables</b>  Injectable local anaesthetic products intended for local, regional or central nerve block in dental practice. These products usually contain higher concentrations of vasoconstrictor or are presented in cartridges which are applicable to a dental injection system.	I1998
<b>N1B3</b>	<b>Anaesthetics local, topical</b>	I1998

N1B9	<p>Topical or surface local anaesthetic products intended for anaesthesia of skin and mucous membranes.</p> <p><b>Anaesthetics local, others</b></p> <p>Local anaesthetic products not classified elsewhere, eg cooling sprays and solutions used in medical procedures, topical products containing benzocaine, etc.</p>	R1999
------	---	-------

<b>N2</b>	<b>ANALGESICS</b>	R2003
	Only includes general purpose analgesics with multiple indications and uses. Thus products specifically used for rheumatic disorders are classified in group M, analgesic cold preparations are classified in R5, products specifically for dysmennorrhoea are classified in G2X.	
<b>N2A</b>	<b>NARCOTICS</b>	R1993
	Includes all analgesics classified as narcotics in accordance with the legal definition of narcotic analgesics in each country.	
<b>N2B</b>	<b>NON-NARCOTICS AND ANTI-PYRETICS</b>	r2017
	Includes systemic products for non-specific analgesia except those classified in N2A (narcotics), N2C (specific anti-migraine preparations), R5A (analgesic/antihistamine cold preparations) and G2X1 (specific dysmenorrhoea preparations).	
	Topical products for analgesia are classified in M2A.	
	Products containing acetylsalicylic acid only are classified in N2B, not M1A.	
	Products containing low-dose oral solid acetylsalicylic acid (162mg and below) are classified in B1C1 (platelet aggregation inhibition).	
	Products containing non-steroidal anti-inflammatories and for both musculoskeletal conditions and analgesia are classified in M1A.	
	Alka-Seltzer, when it contains an analgesic, is classified in N2B. Otherwise, it is classified in A2A1.	
	Products containing muscle relaxants in combination with analgesics are classified in M3.	
	4th level used in Austria, Finland, Hungary, Germany, South Africa, Sweden and Switzerland only.	
<b>N2B1</b>	<b>Prescription-bound non-narcotics and anti-pyretics</b>	
<b>N2B2</b>	<b>Non-prescription-bound non-narcotics and anti-pyretics</b>	
<b>N2C</b>	<b>ANTI-MIGRAINE PREPARATIONS</b>	
<b>N2C1</b>	<b>Antimigraine triptans</b>	I2001
	These are selective 5HT1 receptor agonists eg almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan.	
<b>N2C2</b>	<b>Antimigraine CGRP antagonists</b>	I2020
	Includes products containing CGRP (calcitonin gene-related peptide) antagonists, for example, atogepant, eptinezumab, erenumab, fremanezumab, galcanezumab,	

N2C9	rimegepant, ubrogepant, etc. <b>All other anti-migraine preparations</b> Includes products containing indoramin alone if indicated for migraine.	r2015
------	--	-------

<b>N6</b>	<b>PSYCHOANALEPTICS EXCLUDING ANTI-OBESITY PREPARATIONS</b>	
<b>N6A</b>	<b>ANTI-DEPRESSANTS AND MOOD STABILISERS</b>	R2003
	Includes substances used in the treatment of depression and mood stabilisation. Combinations with ataractics are classified in N6C.	
N6A1	Out of use; can be reused from 2009.	D2006
N6A2	<b>Antidepressants, herbal</b>	R2006
	Includes products containing herbal substances only, eg St. John's Wort. Products containing both a synthetic and a herbal substance are classified in N6A4, N6A5 or N6A9.	
N6A3	<b>Mood stabilisers</b>	R2006
	These products affect the manic phases of bipolar disorders, eg products containing lithium. Includes products containing valproate semisodium when indicated exclusively for mood stabilisation.	
N6A4	<b>SSRI antidepressants</b>	r2014
	Selective serotonin re-uptake inhibitor antidepressants. Includes eg citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline.	
	Products containing paroxetine (7.5mg daily) and indicated for menopausal vasomotor symptoms are classified in G2X9.	
N6A5	<b>SNRI antidepressants</b>	I2006
	Serotonin-noradrenaline re-uptake inhibitor antidepressants. Includes eg duloxetine when used in depression, milnacipran, venlafaxine.	
N6A9	<b>Antidepressants, all others</b>	r2020
	Includes eg amitriptyline, clomipramine, imipramine, mirtazapine, vortioxetine. Products containing esketamine for depression are classified here; products containing esketamine for general anaesthesia are classified in N1A2.	
<b>N6B</b>	<b>PSYCHOSTIMULANTS</b>	R2004
	Includes drugs which increase the psychic and physical performance and which have a fatigue depressing, stimulating effect, eg fentyllines, fencamfamine, methylphenidate, amphetamines (excluding their use in obesity, see A8A). Atomoxetine is classified in N7X.	
<b>N6C</b>	<b>PSYCHOLEPTIC-PSYCHOANALEPTIC COMBINATIONS</b>	r2010
	Includes combinations of tranquillisers and/or antipsychotics with antidepressants.	



N7E	<p><b>DRUGS USED IN ALCOHOL DEPENDENCE</b></p> <p>Includes acamprosate, calcium carbimide, disulfiram. Naltrexone when used in alcohol dependence is classified here.</p>	R2002
N7F	<p><b>DRUGS USED IN OPIOID DEPENDENCE</b></p> <p>Includes naltrexone, except when used in alcohol dependence (use N7E).</p>	R2002
N7X	<p><b>ALL OTHER CNS DRUGS</b></p> <p>Includes parasympathetic agents. Benzodiazepine antagonists such as flumazenil are classified here. Atomoxetine is included in the class. Products containing gabapentin or pregabalin are classified in N3A if indicated for both neuropathic pain and epilepsy.</p> <p>Products containing pilocarpine and indicated for both dry mouth and dry eye are classified here.</p> <p>Products indicated for multiple sclerosis are classified in N7A. Products containing fampridine for improvement in walking in multiple sclerosis are classified here.</p> <p>Products indicated for amyotrophic lateral sclerosis (ALS) are classified here.</p> <p>Products containing tafamidis for transthyretin amyloid polyneuropathy (TAP) only are classified here. Products containing tafamidis for transthyretin amyloid cardiomyopathy (TAC) only are classified in C1X. Products containing tafamidis for both TAP and TAC are classified here.</p>	r2020